Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins

Byron Cryer, Markus Goldschmiedt, Jan S. Redfern, Mark Feldman

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The effects of a 7.5-day course of orally administered salsalate (3.0 g/day), aspirin (3.9 g/day), or placebo on gastroduodenal mucosal injury, mucosal prostaglandin content, and plasma prostaglandin concentrations in healthy, asymptomatic human volunteers were examined. Mean serum salicylate concentrations after these doses of salsalate and aspirin were nearly identical (≈15 mg/dL). When the gastroduodenal mucosa was assessed endoscopically 1 hour after the final dose of medication, there was minimal mucosal injury in placebo-treated or salsalatetreated subjects and considerable injury in the stomach and duodenum of aspirin-treated subjects (P < 0.001, aspirin vs. salsalate or placebo). In both the stomach and duodenum, aspirin lowered mucosal prostaglandin F2a and E2 content by > 90% (P < 0.001), whereas salsalate produced no significant change. Aspirin also lowered plasma prostaglandin F2a concentrations by 58% ± 6%, whereas salsalate lowered them by only 11% ± 9% (P < 0.001). Thus, the nonacetylated salicylate, salsalate, produced much less gastroduodenal mucosal damage than aspirin at equivalent serum salicylate concentrations, possibly because salsalate did not inhibit mucosal prostaglandin synthesis.

Original languageEnglish (US)
Pages (from-to)1616-1621
Number of pages6
JournalGastroenterology
Volume99
Issue number6
StatePublished - 1990

Fingerprint

Aspirin
Prostaglandins
Salicylates
Wounds and Injuries
Placebos
Serum
Duodenum
salicylsalicylic acid
Volunteers
Stomach
Mucous Membrane

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Cryer, B., Goldschmiedt, M., Redfern, J. S., & Feldman, M. (1990). Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins. Gastroenterology, 99(6), 1616-1621.

Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins. / Cryer, Byron; Goldschmiedt, Markus; Redfern, Jan S.; Feldman, Mark.

In: Gastroenterology, Vol. 99, No. 6, 1990, p. 1616-1621.

Research output: Contribution to journalArticle

Cryer, B, Goldschmiedt, M, Redfern, JS & Feldman, M 1990, 'Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins', Gastroenterology, vol. 99, no. 6, pp. 1616-1621.
Cryer, Byron ; Goldschmiedt, Markus ; Redfern, Jan S. ; Feldman, Mark. / Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins. In: Gastroenterology. 1990 ; Vol. 99, No. 6. pp. 1616-1621.
@article{add57921badb4baea545a1394868de7c,
title = "Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins",
abstract = "The effects of a 7.5-day course of orally administered salsalate (3.0 g/day), aspirin (3.9 g/day), or placebo on gastroduodenal mucosal injury, mucosal prostaglandin content, and plasma prostaglandin concentrations in healthy, asymptomatic human volunteers were examined. Mean serum salicylate concentrations after these doses of salsalate and aspirin were nearly identical (≈15 mg/dL). When the gastroduodenal mucosa was assessed endoscopically 1 hour after the final dose of medication, there was minimal mucosal injury in placebo-treated or salsalatetreated subjects and considerable injury in the stomach and duodenum of aspirin-treated subjects (P < 0.001, aspirin vs. salsalate or placebo). In both the stomach and duodenum, aspirin lowered mucosal prostaglandin F2a and E2 content by > 90{\%} (P < 0.001), whereas salsalate produced no significant change. Aspirin also lowered plasma prostaglandin F2a concentrations by 58{\%} ± 6{\%}, whereas salsalate lowered them by only 11{\%} ± 9{\%} (P < 0.001). Thus, the nonacetylated salicylate, salsalate, produced much less gastroduodenal mucosal damage than aspirin at equivalent serum salicylate concentrations, possibly because salsalate did not inhibit mucosal prostaglandin synthesis.",
author = "Byron Cryer and Markus Goldschmiedt and Redfern, {Jan S.} and Mark Feldman",
year = "1990",
language = "English (US)",
volume = "99",
pages = "1616--1621",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins

AU - Cryer, Byron

AU - Goldschmiedt, Markus

AU - Redfern, Jan S.

AU - Feldman, Mark

PY - 1990

Y1 - 1990

N2 - The effects of a 7.5-day course of orally administered salsalate (3.0 g/day), aspirin (3.9 g/day), or placebo on gastroduodenal mucosal injury, mucosal prostaglandin content, and plasma prostaglandin concentrations in healthy, asymptomatic human volunteers were examined. Mean serum salicylate concentrations after these doses of salsalate and aspirin were nearly identical (≈15 mg/dL). When the gastroduodenal mucosa was assessed endoscopically 1 hour after the final dose of medication, there was minimal mucosal injury in placebo-treated or salsalatetreated subjects and considerable injury in the stomach and duodenum of aspirin-treated subjects (P < 0.001, aspirin vs. salsalate or placebo). In both the stomach and duodenum, aspirin lowered mucosal prostaglandin F2a and E2 content by > 90% (P < 0.001), whereas salsalate produced no significant change. Aspirin also lowered plasma prostaglandin F2a concentrations by 58% ± 6%, whereas salsalate lowered them by only 11% ± 9% (P < 0.001). Thus, the nonacetylated salicylate, salsalate, produced much less gastroduodenal mucosal damage than aspirin at equivalent serum salicylate concentrations, possibly because salsalate did not inhibit mucosal prostaglandin synthesis.

AB - The effects of a 7.5-day course of orally administered salsalate (3.0 g/day), aspirin (3.9 g/day), or placebo on gastroduodenal mucosal injury, mucosal prostaglandin content, and plasma prostaglandin concentrations in healthy, asymptomatic human volunteers were examined. Mean serum salicylate concentrations after these doses of salsalate and aspirin were nearly identical (≈15 mg/dL). When the gastroduodenal mucosa was assessed endoscopically 1 hour after the final dose of medication, there was minimal mucosal injury in placebo-treated or salsalatetreated subjects and considerable injury in the stomach and duodenum of aspirin-treated subjects (P < 0.001, aspirin vs. salsalate or placebo). In both the stomach and duodenum, aspirin lowered mucosal prostaglandin F2a and E2 content by > 90% (P < 0.001), whereas salsalate produced no significant change. Aspirin also lowered plasma prostaglandin F2a concentrations by 58% ± 6%, whereas salsalate lowered them by only 11% ± 9% (P < 0.001). Thus, the nonacetylated salicylate, salsalate, produced much less gastroduodenal mucosal damage than aspirin at equivalent serum salicylate concentrations, possibly because salsalate did not inhibit mucosal prostaglandin synthesis.

UR - http://www.scopus.com/inward/record.url?scp=0025201376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025201376&partnerID=8YFLogxK

M3 - Article

C2 - 2227277

AN - SCOPUS:0025201376

VL - 99

SP - 1616

EP - 1621

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 6

ER -